HC Wainwright Increases Larimar Therapeutics (NASDAQ:LRMR) Price Target to $16.00
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) had its price target hoisted by investment analysts at HC Wainwright from $15.00 to $16.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright also issued estimates for Larimar Therapeutics’ Q1 2025 earnings at ($0.43) EPS, Q2 2025 […]
More Stories
Formula One Group (NASDAQ:FWONK) Raised to Sell at StockNews.com
StockNews.com upgraded shares of Formula One Group (NASDAQ:FWONK – Free Report) to a sell rating in a research note published...
Cabot (NYSE:CBT) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of Cabot (NYSE:CBT – Free Report) from a hold rating to a buy rating in a research...
StockNews.com Upgrades Diversified Healthcare Trust (NASDAQ:DHC) to Hold
StockNews.com upgraded shares of Diversified Healthcare Trust (NASDAQ:DHC – Free Report) from a sell rating to a hold rating in...
Altria Group (NYSE:MO) Downgraded to “Hold” Rating by Deutsche Bank Aktiengesellschaft
Deutsche Bank Aktiengesellschaft downgraded shares of Altria Group (NYSE:MO – Free Report) from a buy rating to a hold rating...
United Parcel Service (NYSE:UPS) Price Target Cut to $90.00 by Analysts at Barclays
United Parcel Service (NYSE:UPS – Get Free Report) had its price objective dropped by equities researchers at Barclays from $100.00...
Zepp Health (NYSE:ZEPP) PT Set at $13.87 by Fundamental Research
Fundamental Research set a $13.87 target price on Zepp Health (NYSE:ZEPP – Free Report) in a report released on Tuesday,BayStreet.CA...